DrugBaron

APRIL 13, 2020

This gives a clear indication of current (or very recent) infection, but it tells us nothing about the cumulative number of people exposed, nor the degree or nature of their immune response to the virus. The solution is a test for the immune response to the virus (often called a “serology test”).

Immune Response 100

Immune Response Virus Vaccine Production 100

PLOS: DNA Science

OCTOBER 12, 2023

Can they deliver healing genes without triggering an overactive immune response? The details are disturbingly reminiscent of the famous case of Jesse Gelsinger , who died from a ferocious immune response to experimental gene therapy in September 1999. An immune response is two-tiered.

Therapies 69

Therapies Immune Response DNA Virus 69

Drug Target Review

JUNE 6, 2023

Natural killer (NK) cells are another immune cell type that, as the name suggests, also have potent cell-killing activity, and have a well-known role in the anti-tumour immune response. In the context of a tumour microenvironment, Tregs are often present in high numbers, preventing an effective immune response to the tumour.

Engineering 98

Engineering Immune Response Biochemical Pharmacology Clinical Trials 98

The Pharma Data

OCTOBER 23, 2020

A solidarity clinical trial “is one of the largest international randomized trials for Covid-19 treatments, enrolling almost 12,000 patients in 500 hospital sites in over 30 countries”, according to the World Health Organization (WHO), which launched the trail with a number of partners.

Trials 52

Trials Immune Response Hospitals Clinical Trials 52

The Pharma Data

MARCH 25, 2021

today announced primary results from the Phase 2/3 RELATIVITY-047 (CA224-047) trial evaluating the fixed-dose combination of relatlimab, an anti-LAG-3 antibody, and Opdivo (nivolumab) versus Opdivo alone in patients with previously untreated metastatic or unresectable melanoma. Source link:[link].

Trials 52

Trials Clinical Trials Immune Response Therapies 52

Drug Target Review

JANUARY 15, 2024

Onchilles Pharma has translated this breakthrough research into a proprietary set of therapeutics and plans to start first-in-human clinical trials for its first programme, N17350, in 2024 in skin cancers, head and neck cancer, and triple-negative breast cancer. Activation of the ELANE pathway appears pivotal. Reference 1. Cell [Internet].

Treatment 106

Treatment Immune Response Therapies Clinical Trials 106

Conversations in Drug Development Trends

JUNE 21, 2024

Worldwide Clinical Trials attends each year to hear from the research community, connect with our sponsors and sites, and explore potential partnerships to drive forward novel treatments. Check out this webinar on navigating the landscape of oncology clinical trials. Interested in hearing more insights from Matt?

Clinical Trials 64

Clinical Trials Therapies Clinical Research Immune Response 64

The Pharma Data

NOVEMBER 12, 2020

12 November 2020 — The CALAVI Phase II trials for Calquence (acalabrutinib) in patients hospitalised with respiratory symptoms of COVID-19 did not meet the primary efficacy endpoint. No new safety signal for Calquence was observed in the trials. No new safety signal for Calquence was observed in the trials.

Trials 52

Trials Clinical Trials Immune Response FDA Approval 52

The Pharma Data

OCTOBER 19, 2020

Two presentations will be delivered by Nanobiotix and two will be delivered by the University of Texas MD Anderson Cancer Center. The physical and universal mode of action (MoA) of NBTXR3 is designed to trigger cellular destruction death and adaptive immune response.

Clinical Trials 52

Clinical Trials Immune Response Trials Therapies 52

The Pharma Data

DECEMBER 16, 2020

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. NVX-CoV2373 is being evaluated in an ongoing Phase 3 trial in the U.K. and Australia. About Matrix-M.

Vaccine 52

Vaccine Government Immune Response Clinical Trials 52

The Pharma Data

FEBRUARY 18, 2022

Findings show that the percentage of patients achieving clinical remission, clinical response, endoscopic improvement and corticosteroid-free remission was maintained through Week 142. Additional Bristol Myers Squibb-sponsored abstracts presented at the ECCO 2022 Congress can be accessed online here. About Ulcerative Colitis.

Clinical Trials 40

Clinical Trials Treatment Immune Response Disease 40

The Pharma Data

SEPTEMBER 28, 2020

Australian biotech Ena Respiratory has revealed new data demonstrating that its novel nasal spray almost halted replication of the SARS-CoV-2 in animals when used as a prophylactic, showing potential to improve immune response when used alongside COVID-19 vaccines. . We’ve been amazed with just how effective our treatment has been.

Immune Response 52

Immune Response Small Molecule Virus Vaccine 52

The Pharma Data

MARCH 9, 2021

The trial was conducted among 237 adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed while on or after previous platinum-based chemotherapy and PD-(L)1 inhibitor immunotherapy 4. Two Phase III CANOPY trials continue, evaluating canakinumab in first-line and adjuvant settings 2,3.

Treatment 52

Treatment Immune Response Trials Clinical Trials 52

The Pharma Data

APRIL 8, 2021

Leadership in DNA damage response demonstrated in multiple presentations for AZD5305, a next-generation PARP1 selective inhibitor. Key presentations will include: Structural disclosure and key preclinical data for AZD5305, a next-generation PARP1 selective inhibitor. Key AstraZeneca presentations during AACR 2021.

DNA 52

DNA Immune Response Therapies Treatment 52

The Pharma Data

OCTOBER 14, 2021

Biogen today announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis (MS). Immune response was measured using immunoglobulin G (IgG) assays. Approximately 92 percent of participants in the analysis received an mRNA vaccine.

Vaccine 52

Vaccine Therapies Immune Response Disease 52

The Pharma Data

NOVEMBER 16, 2020

As Pickard explained, one issue is that some candidate vaccines use only a subset of HSV components, or antigens, to try to generate an immune response. And that may not be enough: One vaccine with that design failed to prevent HSV-2 infection in a clinical trial involving thousands of young women.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

DECEMBER 13, 2020

Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced SYNB1891 has advanced into the combination therapy stage of the ongoing Phase 1 trial. Results of the SYNB1891 Phase 1 study will be presented at a future medical meeting. CAMBRIDGE, Mass. ,

Immune Response 40

Immune Response Treatment Engineering Clinical Trials 40

The Pharma Data

MARCH 8, 2021

The trial was conducted among 237 adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed while on or after previous platinum-based chemotherapy and PD-(L)1 inhibitor immunotherapy 4. Two Phase III CANOPY trials continue, evaluating canakinumab in first-line and adjuvant settings 2,3.

Immune Response 52

Immune Response Clinical Trials Trials Treatment 52

The Pharma Data

JANUARY 25, 2021

25, 2021 — Giving melanoma patients a “personalized” vaccine can prompt an anti-tumor immune response that lasts for years, an early study finds. But it builds on earlier work showing it is possible to spur the immune system to respond to an individual’s unique tumor. MONDAY, Jan.

Vaccine 52

Vaccine Immune Response Medical Schools Clinical Trials 52

The Pharma Data

NOVEMBER 9, 2020

The results were presented at The Society for the Immunotherapy of Cancer 35 th Anniversary Annual Meeting. Taken together, these barriers present a significant unmet need to improve the efficacy ICIs and expand their potentially curative benefits to more patients with advanced cancers. Addressing Unmet Needs in Cancer Immunotherapy.

Immune Response 40

Immune Response Therapies Clinical Trials Treatment 40

The Pharma Data

AUGUST 16, 2021

Primary and all key secondary endpoints including itch, interference of itch on sleep and quality of life were met at Week 16 in two pivotal Phase 3 trials in lebrikizumab clinical trial program – Safety profile consistent with prior lebrikizumab studies in atopic dermatitis. Almirall S.A.’s About Atopic Dermatitis.

Trials 40

Trials Clinical Trials Small Molecule Disease 40

Olympian Clinical Research

DECEMBER 19, 2023

With ongoing research and clinical trials , institutions like Olympian Clinical Research are at the forefront of finding innovative treatment options. These patches present more than physical discomfort. For more severe cases, systemic medications, including newer biologics that target immune responses, are used.

Clinical Research 52

Clinical Research Clinical Trials Treatment Immune Response 52

The Pharma Data

OCTOBER 14, 2020

We are evaluating APX005M in a broad clinical program that includes more than 10 clinical trials in various indications and therapeutic combinations,” said Xiaodong Yang , MD, PhD, Chief Executive Officer of Apexigen. APX005M is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response.

Treatment 40

Treatment Immune Response Clinical Trials Clinical Development 40

DrugBank

MAY 6, 2024

These conditions, typically managed with steroids or dietary adjustments, might experience a paradigm shift if these investigational biologics, which target specific inflammatory pathways, are proven effective in clinical trials and gain subsequent approval. Yet, the road ahead is not without its bumps.

FDA Approval 65

FDA Approval Therapies Treatment Clinical Trials 65

The Pharma Data

DECEMBER 10, 2020

The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. The study showed this broad immune response led to the complete clearance of the virus in a matter of days after infection of previously-vaccinated primates.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

DECEMBER 16, 2020

Throughout the day, various presentations will be given by medical experts pertaining to Emergency Use Authorization (EUA). Instead, it uses a genetic code, which tricks the body into developing an immune response to the virus. The meeting is slated to run from 9 a.m. ET to 5:15 p.m. ET, according to a draft of the agenda.

Vaccine 52

Vaccine Immune Response FDA FDA Approval 52

The Pharma Data

OCTOBER 26, 2020

Novavax will present data from an ongoing Phase I/II clinical trial, including new Phase II reactogenicity data from its COVID-19 vaccine candidate. CoV2373 on Friday during the CDC’s Advisory Committee on Immunization Practices’ (ACIP) meeting. Please read more here. . Days after the U.S. Organizational Actions/Announcements

Vaccine 52

Vaccine FDA Approval FDA Clinical Trials 52

The Pharma Data

OCTOBER 16, 2020

15, 2020 — Point-of-care testing is associated with large reductions in the time to results for patients presenting with suspected COVID-19, according to a study published online Oct. Immune Responses Long-Lasting After Serious COVID-19. NIH Launches Trial of Antibody Drugs Against COVID-19. THURSDAY, Oct.

Immune Response 52

Immune Response Hospitals Trials Vaccine 52

Drug Target Review

APRIL 3, 2024

Our research demonstrated that GDF-15 acts as a versatile tool for tumours to inhibit the mounting of an effective antitumoral immune response at various steps of its process, including antigen presentation, immune cell activation, and their migration and infiltration into the tumour. in North America) in late 2017.

Science 106

Science Clinical Development Treatment DNA 106

The Anticancer Fund

JUNE 23, 2023

Please get in touch if you’re interested in discussing research based on the findings presented below ( info@anticancerfund.org ). However, this was not an efficacy trial and similar responses have been seen from chemo alone. More informative Phase 2 trials are necessary to assess whether metformin improves outcomes.

Drugs 52

Drugs Trials Clinical Trials Treatment 52

The Pharma Data

JANUARY 22, 2021

Pending ImmunityBio’s discussions with the US Food and Drug Administration , the oral vaccine will enter Phase 1 trials as a prime and boost, and will be explored as an option to provide healthcare providers with a boost to subcutaneous vaccinations.

Vaccine 52

Vaccine Immune Response Government RNA 52

The Pharma Data

OCTOBER 19, 2020

Immune responses following vaccination with PNEUMOVAX 23 (month 13) were comparable in both vaccination groups for the 15 serotypes in V114. Results from both studies are based on opsonophagocytic activity (OPA) responses – a measure of vaccine-induced functional antibodies.

Vaccine 52

Vaccine Immune Response Disease Clinical Trials 52

Drug Target Review

OCTOBER 2, 2024

Early-phase clinical trials have shown the safety and efficacy of using stem cells for cardiac repair, encouraging further research and development. While commonly used, AAVs have limitations, including immune reactions and difficulties with re-dosing due to pre-existing antibodies.

Therapies 52

Therapies Disease Engineering RNA 52

SugarCone Biotech

MAY 28, 2019

This broader and still evolving contextual framework will impact immunotherapy drug development across the immune checkpoint field, the tumor vaccine space, innate immune approaches, the T-cell-directed biologics, and cellular therapies. But first, these new papers are gorgeous: The study presented by Petitprez et al.

Immune Response 52

Immune Response Therapies Production Vaccine 52

The Pharma Data

JULY 6, 2021

New research from first-in-class marketed and investigational therapies in hemophilia, immune thrombocytopenia and acquired thrombotic thrombocytopenic purpura will be presented. Oral presentation. Interim Phase 1/2 study data will be presented at ISTH. Oral Presentation. ePoster Abstract # OC48.2 Abstract # OC72.2

Therapies 52

Therapies Pharmacokinetics RNA Treatment 52

The Pharma Data

MARCH 27, 2023

Entyvio ® should be used only in patients with inadequate response to conventional treatment. This approval is based on the MLN0002SC-3027 and MLN0002SC-3030 clinical trials, which are international Phase III trials to evaluate the efficacy and safety of Entyvio SC as a maintenance therapy.

Treatment 40

Treatment Marketing Pharmaceutical Companies Immune Response 40

The Pharma Data

MARCH 25, 2021

Regulatory submissions for TAK-003 include long-term safety and efficacy data through 36 months from the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial. Takeda intends to present and publish details of the 36-month data at a scientific meeting and in a peer-reviewed journal this year.

Vaccine 52

Vaccine Virus Trials Hospitals 52